Amikacin

Verify with FDA CVM →

67 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
67
Total Reports
13
Deaths Reported
1940.0%
Death Rate

Active Ingredients

Amikacin

Administration Routes

UnknownIntra-ArticularParenteralTopicalAuricular (Otic)OtherIntravenousIntramuscular

Species Affected

Horse 31
Dog 21
Unknown 9
Cat 6

Most Affected Breeds

Quarter Horse 13
Unknown 9
Horse (unknown) 8
Cat (unknown) 3
Crossbred Canine/dog 3
Domestic Shorthair 3
Trakehner 3
Bulldog 3
Warmblood (unspecified) 2
Crossbred Equine/horse 2

Most Reported Reactions

Death by euthanasia 9
Elevated alanine aminotransferase (ALT) 8
Lameness 7
Other abnormal test result NOS 7
Decreased appetite 7
Elevated blood urea nitrogen (BUN) 7
Joint swelling 6
Leucocytosis NOS 6
Lack of efficacy - NOS 6
Swelling NOS 6
Elevated aspartate aminotransferase (AST) 6
Elevated creatinine 6

Outcome Breakdown

Ongoing
19 (34.5%)
Recovered/Normal
14 (25.5%)
Outcome Unknown
9 (16.4%)
Euthanized
9 (16.4%)
Died
4 (7.3%)

Data Summary

Metric Value
Total adverse event reports 67
Reports involving death 13
Case-fatality rate (reported events) 1940.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Amikacin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 67 adverse event reports referencing Amikacin, including 13 reports in which the animal died — a 1940.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Amikacin. Reported administration routes include Unknown, Intra-Articular, Parenteral, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Amikacin reports are Horse (31 reports), Dog (21 reports), Unknown (9 reports), with Horse accounting for the largest share. Within those species, Quarter Horse (13), Unknown (9), Horse (unknown) (8) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Amikacin are Death by euthanasia (9), Elevated alanine aminotransferase (ALT) (8), Lameness (7), Other abnormal test result NOS (7). Of the 55 reports with a coded outcome, Ongoing is the leading category at 34.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Amikacin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial